Dublin, Ireland-based Horizon Pharma plc is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases.
The company operates through three business units – Orphan, Primary Care and Rheumatology. Its portfolio currently comprises nine marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis) and Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis) among others.
The company has been actively pursuing acquisitions to expand and diversify its portfolio. In this scenario, investor focus remains on the company’s performance apart from the usual top-and bottom-line numbers.
Horizon beat earnings estimates by 18.18% in the last quarter. Overall, Horizon has beaten earnings estimates thrice in the four quarters with an average positive surprise of 67.69%. Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Horizon Pharma’s fourth-quarter 2017 earnings easily beat expectations. Our consensus called for EPS of 22 cents, and the company reported EPS of 29 cents.
Revenues: Revenues in the reported quarter also beat expectations. Horizon Pharma posted revenues of $274.2 million which surpassed our consensus estimate of $267.58 million.
Key Stats: The company generated strong performance in its rheumatology and orphan business units, with sales of Krystexxa and Ravicti rising 48% and 57%. However, sales from primary care business unit declined due to the implementation of the new contracting model with pharmacy benefit managers. In December, the FDA approved a label expansion for Procysbi to include children aged one year and above suffering from nephropathic cystinosis.
2018 Outlook: The company provided its outlook for 2018 and expects sales in the range of $1.15 billion to $1.18 billion in 2018. Horizon Pharma expects Krystexxa to continue its performance with the drug’s sales expect to grow more than 50%.
Pre-Market Trading: Shares were inactive in pre-market trading.
Check back later for our full write up on this HZNP earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Image: Bigstock
Horizon Pharma (HZNP) Tops Q4 Earnings, Revenues Beat
Dublin, Ireland-based Horizon Pharma plc is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases.
The company operates through three business units – Orphan, Primary Care and Rheumatology. Its portfolio currently comprises nine marketed products. Key products include Actimmune (chronic granulomatous disease and severe malignant osteopetrosis) and Duexis (signs and symptoms of osteoarthritis and rheumatoid arthritis) among others.
The company has been actively pursuing acquisitions to expand and diversify its portfolio. In this scenario, investor focus remains on the company’s performance apart from the usual top-and bottom-line numbers.
Horizon beat earnings estimates by 18.18% in the last quarter. Overall, Horizon has beaten earnings estimates thrice in the four quarters with an average positive surprise of 67.69%. Currently, Horizon Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Horizon Pharma’s fourth-quarter 2017 earnings easily beat expectations. Our consensus called for EPS of 22 cents, and the company reported EPS of 29 cents.
Revenues: Revenues in the reported quarter also beat expectations. Horizon Pharma posted revenues of $274.2 million which surpassed our consensus estimate of $267.58 million.
Key Stats: The company generated strong performance in its rheumatology and orphan business units, with sales of Krystexxa and Ravicti rising 48% and 57%. However, sales from primary care business unit declined due to the implementation of the new contracting model with pharmacy benefit managers. In December, the FDA approved a label expansion for Procysbi to include children aged one year and above suffering from nephropathic cystinosis.
2018 Outlook: The company provided its outlook for 2018 and expects sales in the range of $1.15 billion to $1.18 billion in 2018. Horizon Pharma expects Krystexxa to continue its performance with the drug’s sales expect to grow more than 50%.
Pre-Market Trading: Shares were inactive in pre-market trading.
Check back later for our full write up on this HZNP earnings report later!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>